A Study of IMC008 for Advanced Solid Tumors

Inclusion Criteria: * Advanced gastric cancer /esophagogastric junction adenocarcinoma advanced pancreatic cancer. * Tumor tissue samples of subjects expected to be available with positive for CLDN18.2 immunohistochemistry. * The expected survival period of the subject is ≥12 weeks. * The subject needs to have at least one target lesion that can be stably evaluated. * The ECOG score is 0-1. * Subject has adequate organ and bone marrow function * All toxic reactions caused by previous anti-tumor therapy were relieved to grade 0-1. * Fertility status : Women of childbearing age or men whose sexual partners are women of childbearing age are willing to take medically approved high-efficiency contraceptive measures. * Subjects must sign and date written informed consent. Exclusion Criteria: * Pregnant and lactating women. * Known history of human immunodeficiency virus infection; acute or chronic active hepatitis B; acute or chronic active hepatitis C. Syphilis antibody positive; Epstein-Barr virus infection; CMV infection. * Serious infection that is active or poorly controlled clinically. * Uncontrollable pleural effusion, pericardial effusion, peritoneal effusion existed before enrollment. * Extensive or diffuse lung metastases or extensive or diffuse liver metastases. * Oxygen saturation ≤ 95% without oxygen inhalation. * Suffering from other research diseases that may limit their participation in this study. * Known past or current hepatic encephalopathy requiring treatment; patients with current or history of central nervous system disease. * There are heart diseases that need to be treated or hypertension that is poorly controlled by the investigator, poorly controlled after standard treatment type 2 diabetes mellitus. * Presence of any cardiac clinical symptoms or disorders. * Evidence of significant coagulopathy or other significant bleeding risk. * Received systemic steroids equivalent to \>15 mg/ day prednisone cumulatively for more than 3 days within 2 weeks prior to apheresis , excluding inhaled steroids. * Prior or concurrent occurrence of other malignancies, with the following exceptions. * Subjects who have previously received other gene therapy. * Allergic/ intolerance to lymphodepletion regimen or CRS treatment drugs or IMC008. * Subjects with severe mental disorders. * The investigator assessed the subject's inability or unwillingness to comply with the requirements of the study protocol .